Why BridgeBio Pharma, Inc.’s BBP-418 priority review could redefine the future of LGMD treatment
BridgeBio Pharma, Inc.’s BBP-418 wins FDA Priority Review for LGMD2I/R9. Discover what this could mean for rare muscular dystrophy treatment.
Pharma & Biotech
Pharma & Biotech
BridgeBio Pharma advances BBP-418 toward FDA filing after Phase 3 muscular dystrophy trial data
BridgeBio Pharma reports Phase 3 BBP-418 results and prepares FDA filing. Could this become the first therapy for limb-girdle muscular dystrophy?